Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
08 août 2024 07h00 HE
|
Verve Therapeutics
Heart-2 clinical trial of VERVE-102 enrolling in the U.K. and Canada; Clinical Trial Application cleared in Australia Heart-2 and PCSK9 program data update planned for first half of 2025 Phase...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02 août 2024 16h05 HE
|
Verve Therapeutics
BOSTON, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on July 31, 2024,...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
01 juil. 2024 16h05 HE
|
Verve Therapeutics
BOSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
28 juin 2024 07h00 HE
|
Verve Therapeutics
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
31 mai 2024 16h01 HE
|
Verve Therapeutics
BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Leadership Update
31 mai 2024 07h00 HE
|
Verve Therapeutics
Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 (GLOBE NEWSWIRE) --...
Verve Therapeutics to Participate in Upcoming Investor Conferences
30 mai 2024 16h01 HE
|
Verve Therapeutics
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
08 mai 2024 07h00 HE
|
Verve Therapeutics
First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102 VERVE-201 clinical trial initiation on track for the second half of 2024 Received first milestone payment from Eli Lilly for...
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
07 mai 2024 07h00 HE
|
Verve Therapeutics
VERVE-102 is an investigational in vivo base editing medicine designed to permanently inactivate the PCSK9 gene in the liver to durably reduce blood low-density lipoprotein cholesterol Heart-2...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03 mai 2024 16h01 HE
|
Verve Therapeutics
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...